Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High - Should You Buy?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $131.40 and last traded at $131.30, with a volume of 1500320 shares trading hands. The stock had previously closed at $131.36.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of research analyst reports. StockNews.com began coverage on Intra-Cellular Therapies in a research note on Thursday. They issued a "hold" rating on the stock. Baird R W downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Finally, Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price objective for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of "Hold" and an average price target of $106.08.

Remove Ads

Intra-Cellular Therapies Trading Up 0.0 %

The business has a fifty day moving average of $127.87 and a 200-day moving average of $97.01. The firm has a market cap of $14.00 billion, a PE ratio of -151.32 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Accredited Wealth Management LLC bought a new stake in Intra-Cellular Therapies during the fourth quarter valued at $28,000. True Wealth Design LLC bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at about $32,000. GAMMA Investing LLC grew its holdings in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Intra-Cellular Therapies in the fourth quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $97,000. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.